Deliver genes to any cell with AI
TLDR Nanograb is announcing NGX1, a universal navigation system for mRNA drugs to deliver cures for any disease. Moderna proved that mRNA will transform skin cancer care, we expand this to all diseases.
Delivery is one of the most important problems stopping life-changing mRNA drugs reaching millions. There are over 3,000 different cell types in the body, but mRNA drug developers can only hit 1% of them. The problem is so pressing that multiple public biopharma partners are paying for early access to NGX1.
Works the first time, every time. There are more peptide sequences than atoms in the universe. Most approaches to solve delivery rely on screening thousands of formulations. NGX1’s biophysics-informed models achieved >25% hit rates on the first try across different targets in mice (4x improvement in cancer cells, 15x for immune cells).
We hit any cell, any state. All cells have receptors. Their combination makes up a unique fingerprint. Most people try and target individual receptors whereas we can target the fingerprint, enabled by multivalent physics. We’re creating new drugs that have never existed before.
NGX1 solves major scale-up issues upfront. Scaling up targeted mRNA drugs to millions of people is hard because of complex biomanufacturing requirements. Nanograb circumvents these requirements by utilising short peptides instead of antibodies or other biologics.
15 years of physics research powers NGX1. Our team includes the foundational researchers of the multivalent biophysics models powering our platform. Our founding team are scientists from Imperial, Oxford and Cambridge.
Moderna has already shown that mRNA drugs are the future. Eli Lilly showed that mRNA’s potential to be a one-time solution for high cholesterol could help the entire global population. NGX1 is the first step to realising a future where millions of people can access mRNA therapies.
Learn more at nanograb.com or reach out via platform@nanograb.com.
